Navigation Links
PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis
Date:12/4/2012

., EntreMed's Chief Executive Officer further commented, "In addition to ENMD-2076 for oncology, 2ME2 represents another important asset for our company with its strong IP position and sound safety profile.  Together with our previous findings of its disease modifying activity in RA animal models, this study further extends 2ME2's therapeutic value to the management of MS, RA and possibly other autoimmune disorders."

Dr. Ren continued, "We appreciate the international recognition by our peers.  For the next step, we intend to further advance 2ME2 development as part of our global drug development plan and strategy to leverage resources both in the US and China.  We are currently exploring multiple strategies for the development of 2ME2 including possible partnership opportunities.  We believe that the development of 2ME2 for autoimmune diseases fits well with our plan to build a robust product pipeline and to add value for our long term shareholders."

The article is entitled "2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation" and was authored by Gordon S. Duncan, Dirk Brenner, Michael W. Tusche, Anne Brustle, Christiane B. Knobbe, Andrew J. Elia, Thomas Mock, Mark R. Bray, Peter H. Krammer and Tak W. Mak.  The article is available at http://www.pnas.org/content/early/2012/11/30/1215558110.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for cancer, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
2. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
3. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
4. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
5. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
6. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
7. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
8. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  VentiRx Pharmaceuticals, Inc., a clinical stage ... commercialization of novel Toll-like receptor 8 (TLR8) ... and clinical activities at the company including ... clinical trials and future clinical development efforts. ... Officer Robert Hershberg , M.D., Ph.D. ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... OAKS, Calif. , Sept. 2, 2014 ... today announced the submission of a Marketing ... Agency (EMA) via the centralized procedure for ... of adults with melanoma that is regionally ... oncolytic immunotherapy administered as an intralesional injection ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... may help scientists learn why patients with cystic fibrosis ... their lungs are relatively healthy. , The researchers ... treat pulmonary hypertension and Viagra for erectile dysfunction ... help them identify the root of the blood vessel ... , "We want to understand why these patients have ...
(Date:9/2/2014)... there might be a new salve to dominate medicine cabinets ... lowly salamander. Salamanders may not be the cuddliest of animals, ... of seriously damaged body parts. Now, a new report published ... Journal , identifies a small protein (called a "peptide") ... to unlocking the secret of this amazing wound healing trick ...
(Date:9/2/2014)... of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased ... Fellowship. This two-year fellowship, founded in 2008 by the ... Kanji Torizuka, MD, PhD, is designed to provide extensive ... and molecular imaging for Japanese physicians in the early ... proud to sponsor the Wagner-Torizuka Fellowship. This program honors ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... moms have lower rates of depression than their stay-at-home counterparts, ... at greater risk for depression, suggests new research to be ... Association. The study shows that working mothers who ... be blended with relative ease showed higher levels of depression ...
... Paper money worldwide is contaminated with the potentially toxic chemical ... is used to make some plastics and consumer products such ... that BPA is an endocrine disruptor, which means that it ... to a number of health problems. Researchers analyzed 156 ...
... Aug. 19 (HealthDay News) -- Some patients do dream while ... still have a form of consciousness about themselves and the ... electroencephalography (EEG) to compare the structure of sleep in 11 ... five in a vegetative state (unresponsive wakefulness). "We used ...
... can reduce the risk of strokes as well as heart ... System neurologists caution that statins may not be appropriate for ... The article, by Dr. Murray Flaster and colleagues, appears in ... Neurotherapeutics . , A landmark 2006 study known as SPARCL, ...
... , THURSDAY, Aug. 18 (HealthDay News) -- A calcium ... to provide insight into the likelihood that certain patients at ... or stroke, researchers say. The test to detect ... take cholesterol-lowering drugs to reduce their cardiovascular risks, the study ...
... For better or for worse, in sickness and in ... associates marriage with reducing unhealthy habits such as smoking, ... However, new research is emerging that suggests married straight ... intimate relationships may pick up each other,s unhealthy habits ...
Cached Medicine News:Health News:Less depression for working moms who expect that they 'can't do it all' 2Health News:Paper Money Worldwide Tainted With BPA: Study 2Health News:People Appear to Dream While in Minimally Conscious State 2Health News:Cholesterial drugs can reduce the risk of stroke, but aren't for everyone 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:Long-term, intimate partnerships can promote unhealthy habits 2Health News:Long-term, intimate partnerships can promote unhealthy habits 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: